Curated News
By: NewsRamp Editorial Staff
December 18, 2025
CD BioSciences Launches One-Stop Anti-Aging Drug Development Service
TLDR
- CD BioSciences offers pharmaceutical companies a competitive edge with comprehensive anti-aging drug development services that accelerate R&D timelines and reduce entry barriers.
- CD BioSciences provides a systematic anti-aging drug development process covering target verification, lead compound screening, preclinical models, pharmacology, pharmacokinetics, and safety evaluation.
- This service advances anti-aging therapeutics that could extend healthy lifespans and improve quality of life for aging populations worldwide.
- CD BioSciences uses diverse aging models including naked mole-rats and zebrafish to test drugs targeting pathways like mTOR and SIRT1.
Impact - Why it Matters
This development significantly lowers barriers to entry in the rapidly growing longevity sector, potentially accelerating the timeline for bringing effective anti-aging therapies to market. For researchers and pharmaceutical companies, it provides access to specialized expertise and a comprehensive suite of tools—from target discovery to preclinical models—that would be costly and time-consuming to develop in-house. For the general public, it represents a step forward in translating scientific understanding of aging into tangible medical interventions, which could one day lead to treatments that extend healthspan and combat age-related diseases like Alzheimer's and cardiovascular conditions. By streamlining R&D, this service could foster more innovation and collaboration in a field poised to redefine healthcare and human longevity.
Summary
CD BioSciences, a specialized preclinical research service provider in the longevity field, has launched a comprehensive one-stop anti-aging drug development service package. This initiative targets pharmaceutical companies, research institutions, and academic investigators, aiming to streamline the lengthy and complex process of developing cutting-edge anti-aging therapeutics. As a professional Contract Research Organization (CRO), the company leverages its industry-leading experience and technical platforms to support partners throughout the entire drug development cycle, from early discovery to preclinical stages.
The core of the offering lies in its diversified anti-aging drug discovery services, which provide customized solutions across a wide spectrum of targets and drug types. Key molecular targets covered include AMPK, mTOR, SIRT1, NF-κB, p53, and PI3K—pathways closely linked to aging mechanisms. For drug types, the service encompasses senolytics, senomorphics, calorie restriction mimetics, autophagy inducers, and more, meeting diverse client needs for target verification and lead compound screening. The company's comprehensive anti-aging drug development services further extend into a complete preclinical system, covering critical areas like pharmacology, pharmacokinetics (ADME/PK), and safety evaluation to ensure scientific rigor and data reliability.
As a specialized aging disease model CRO, CD BioSciences has also built a robust and customizable preclinical aging model platform. This platform includes organ-specific aging models, general aging models, longevity models, and aging-related disease models, such as those for neurodegenerative and cardiovascular diseases. These models are designed to effectively assist clients in uncovering aging mechanisms, validating therapeutic targets, and evaluating the efficacy and safety of candidate drugs. The launch of this integrated service suite addresses key industry challenges like lengthy timelines and high entry barriers in anti-aging R&D, positioning CD BioSciences as a strategic partner to accelerate innovation and the transformation of anti-aging therapeutics globally.
Source Statement
This curated news summary relied on content disributed by 24-7 Press Release. Read the original source here, CD BioSciences Launches One-Stop Anti-Aging Drug Development Service
